Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study.
Luis M RuilopeBertram PittStefan D AnkerEllen BurgessCsaba Pal KovesdyRoberto Pecoits-FilhoPablo PergolaAmer JosephAndrea LageNicole MentenichMarkus F ScheererGeorge L BakrisPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022)
The present analyses suggest that finerenone protects against kidney disease progression and cardiovascular events in patients with T2D and early- or late-stage CKD.